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Abstract
Background: There is increasing recognition that establishing a core set of outcomes to be evaluated and reported
in trials of interventions for particular conditions will improve the usefulness of health research. There is no established
core outcome set for childhood epilepsy. The aim of this work is to select a core outcome set to be used in evaluative
research of interventions for children with rolandic epilepsy, as an exemplar of common childhood epilepsy
syndromes.
Methods: First we will identify what outcomes should be measured; then we will decide how to measure those outcomes.
We will engage relevant UK charities and health professional societies as partners, and convene advisory panels for young
people with epilepsy and parents of children with epilepsy. We will identify candidate outcomes from a search for trials of
interventions for childhood epilepsy, statutory guidance and consultation with our advisory panels.
Families, charities and health, education and neuropsychology professionals will be invited to participate in a Delphi survey
following recommended practices in the development of core outcome sets. Participants will be able to recommend
additional outcome domains. Over three rounds of Delphi survey participants will rate the importance of candidate outcome
domains and state the rationale for their decisions. Over the three rounds we will seek consensus across and between
families and health professionals on the more important outcomes. A face-to-face meeting will be convened to ratify the
core outcome set. We will then review and recommend ways to measure the shortlisted outcomes using clinical assessment
and/or patient-reported outcome measures.
Discussion: Our methodology is a proportionate and pragmatic approach to expediently produce a core outcome set for
evaluative research of interventions aiming to improve the health of children with epilepsy. A number of decisions have to
be made when designing a study to develop a core outcome set including defining the scope, choosing which
stakeholders to engage, most effective ways to elicit their views, especially children and a potential role for qualitative
research.
Keywords: Epilepsy, Children, Young people, Paediatric, Core outcome set
* Correspondence: Christopher.Morris@exeter.ac.uk
1Peninsula Cerebra Research Unit (PenCRU) & NIHR Collaboration for
Leadership in Applied Health Research and Care South West Peninsula
(PenCLAHRC), University of Exeter Medical School, Exeter, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Morris et al. Trials  (2017) 18:572 
DOI 10.1186/s13063-017-2323-7
Background
Epilepsy is an umbrella term covering a number of con-
ditions including around 30 different syndromes defined
by persisting tendency for seizures. Our focus is on
school-aged children with rolandic epilepsy, also known
as “childhood epilepsy with centrotemporal spikes” in
the revised International League Against Epilepsy classi-
fication [1]. Rolandic epilepsy is the most common type
of childhood epilepsy (17–25% in the 5–14-year age
range), [2, 3] with prevalence of 1.1 in 1000 children [3].
Onset is typically around 7 years of age and seizures
cease by adolescence. The seizures are focal, often
nocturnal, affecting the face, arm and sometimes whole
body. Seizures in rolandic epilepsy can usually be con-
trolled with monotherapy antiepileptic medication. It is
often associated with speech, attention, language, liter-
acy, and motor impairments but not associated impair-
ments such as autism or intellectual disability [4–6].
The primary outcome in trials evaluating interventions
for epilepsy is typically freedom from seizures, or signifi-
cant reduction in frequency, duration and intensity of
seizures at a defined time point after commencing treat-
ment. However, balance is required between seizure con-
trol and potential side effects of antiepileptic drugs and
the impact these have on children. Health-related quality
of life has also become a focus for research, with the so-
cial and psychological consequences of seizures and
children’s perspectives becoming more valued [7]. At
least 11 questionnaires have been developed to assess
quality of life in children with epilepsy, each with a
slightly different focus [8]. It is salutary to recognise that
epilepsy-specific quality of life is not solely determined
by seizures, but more influenced by the child’s learning,
mental health and social support [9, 10]. The variety of
outcomes assessed and different ways outcomes are
measured, as well as the variable quality of outcome
measures, are a barrier to integrating findings from stud-
ies, hence we need to ascertain a core set of more im-
portant outcomes that matter to families [11].
There is increasing recognition that identifying a core
set of outcomes to be evaluated and reported in all trials
of interventions for particular conditions will improve
the usefulness of research, [12, 13] and avoid waste of
research effort [14]. The development of a core outcome
set (COS) should, at the least, include the views of
patients, carers and health professionals [13]. The COS
may also be useful for other types of research, clinical
audit and as routinely collected health services clinical
data. A COS specifies both what aspects of health are
to be assessed and how the measurement will be
determined.
Currently there is no established core outcome set for
children and young people with epilepsy. The Core Out-
come Measures in Effectiveness Trials (COMET)
Initiative database includes a study focused on West
syndrome [15] and a reference to a core outcome sets
for adults with epilepsy [16]. Children are included in
the Common Data Elements recommended for epilepsy
research by the National Institute of Neurological Disor-
ders and Stroke [17]. This recommends a comprehensive
list of items across various domains but not a core set of
outcomes, and children and parents were not consulted
in that process.
Cochrane reviewers recommend focusing on longer-
term outcomes and psychosocial, quality of life and
health economic outcomes [18]. National Institute for
Health and Care Excellence (NICE) guidance recom-
mends seizure freedom as the primary outcome, and
seizure reduction, quality of life and cognitive function-
ing as secondary outcomes [19]. Scottish guidance
additionally highlights aspects of academic attainment,
anxiety and depression [20]. Adverse effects from treat-
ment that have been monitored include drug toxicity,
daytime sleepiness, behavioural problems, vertigo, head-
aches, nausea/vomiting, diarrhoea, tremor, fatigue and
rashes. The International League Against Epilepsy has
also published general guidance on outcome measure-
ment in clinical trials [21, 22].
Many regulatory agencies now mandate incorporating
patient-reported outcome measures in evaluative
research [23, 24]. Decisions on the adoption or reim-
bursement of new health technologies require evidence
of cost-effectiveness derived from preference-based mea-
sures [25]. However, there remains a lack of consensus
about the optimal way to estimate health utilities, given
that adults, children and young people perceive and
value health differently. Important considerations in the
context of children and young people, therefore, include
the role of proxy reporting of health utilities and the ap-
propriateness and validity of direct and indirect methods
of preference elicitation [26].
The aim of this work is to identify a core set of outcome
measures for rolandic epilepsy. This study will address: (1)
what outcomes to measure and (2) how to measure those
outcomes. These decisions will be considered in consult-
ation with young people with epilepsy, parents, charities
and health, education and psychology professionals. The
involvement of children and parents is crucial, to ensure
the outcomes measured are meaningful to inform deci-
sions about treatment, and to ensure that assessment tools
are appropriate and acceptable.
This study is part of a programme of research aiming
to improve broad health-related quality of life for chil-
dren with epilepsy by evaluating different treatment
strategies. The findings of this study will inform
decisions about outcomes to be measured in a trial
evaluating interventions for rolandic epilepsy scheduled
to begin recruitment in 2019. Our work is motivated by
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the necessity to change the agenda from a seizure-
centred medical model towards broader child and family
priorities, and to focus scarce resources on the most im-
portant outcomes we identify [27].
Methods
The study will be registered with the COMET Initiative
and follows its procedures (Fig. 1). We will seek a propor-
tionate ethics approval through the National Health Service
(NHS) Health Research Authority and informed consent
from participants.
Scope
The study focuses on children of school age (5–16 years
old) with rolandic epilepsy. The work will be conducted in
partnership with families, charities and health professionals
in the UK. The scope includes outcomes of any intervention
where the aim is to improve the health of children with epi-
lepsy and is not limited to drugs. Our primary objective is
to propose a COS for evaluative trials but may also inform
decisions about outcomes to be measured in audits such as
Epilepsy12 [28, 29] and routinely collected services data.
Public involvement in the research
We value involving children, young people and parents
as meaningful partners in carrying out this research [30].
Two parents of children with epilepsy who also have ex-
perience of epilepsy themselves were co-applicants in se-
curing funding. Two advisory panels will be convened,
one with children and young people with epilepsy and
one with parents of children with epilepsy. The advisory
panels will be consulted at all stages where key influen-
tial decisions are required. Members of the panels will
be recruited through liaising with relevant UK charities
(Young Epilepsy, Epilepsy Action, Epilepsy Research,
Epilepsy Society and Cerebra).
Phase 1: identifying candidate outcomes
The following methods are proposed as a proportionate
and expedient approach for creating a list of candidate
outcome domains. We expect duplication where the same
outcomes are measured in numerous studies. We will not
re-record duplicated outcomes unless measurement was
made using a different method. The search will cease
when further searching does not reveal new outcomes.
Search strategy
Candidate outcome domains will be identified from sys-
tematic reviews and primary research studies retrieved
by electronic searches run on the Cochrane Database of
Systematic Reviews, CENTRAL, PsycInfo, CINAHL,
Medline and EMBASE (via Ovidsp) and the World
Fig. 1 Key steps in the process
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Health Organisation International Clinical Trials Regis-
try Platform for ongoing trials. The Turning Research
Into Practice (TRIP) database will be searched for na-
tional statutory guidance documents. The electronic
searches will be carried out by an information specialist
(MR) and results catalogued in Endnote reference man-
ager. The strategy will use both controlled headings (e.g.
medical subject headings (MeSH)) and free text. Terms
will be grouped by concepts and combined accordingly.
The search strategies will be recorded and reported.
Search results will be managed in reference management
software and the dates of searches recorded.
Types of studies
Eligible publications will be systematic reviews of trials, clin-
ical trials and observational studies focusing on children
with epilepsy, and national statutory guidance. We will con-
sider qualitative research or mixed methods studies that re-
port children’s or their parents’ preferences for outcomes.
We will compile a list of epilepsy-specific and generic
patient-reported outcome measures used with children with
epilepsy. Only English-language papers will be included.
Types of interventions
We will include publications on all types of interven-
tions that aim to improve the health of children with
epilepsy, including drug trials, social interventions and
psychological therapies.
Types of participants
Although principally focusing on rolandic epilepsy, we
will include publications of studies that included study
populations comprising up to 50% children (5–16 years
old) with other types of epilepsy. Studies focusing
predominantly on adults as participants will be excluded;
to be eligible, study populations must comprise at least
80% children.
Exclusion criteria
Studies that include children with epilepsy but where
the focus was on any associated impairments (e.g.
cerebral palsy, autism) will be excluded.
Deciding eligibility
The study researcher will screen titles and abstracts and
select references. If there are any doubts about eligibility
the final decision will be made in consultation with
other members of the research team. We do not propose
two people screening as the additional resources are not
justified by the risk of missing outcome domains, as we
expect considerable duplication. A “Preferred reporting
items for systematic reviews and meta-analyses”
(PRISMA) flow chart will be used to record each stage
of the study selection process [31].
Data extraction
The study researcher will record each outcome domain
measured in an eligible paper and the instrument/
method for ascertaining measurement. We will note par-
ticipant characteristics, type of intervention where
appropriate, time to measurement of outcome after the
intervention was started and any other salient details
relating to the practicalities of measurement. Data ex-
tracted will be checked for accuracy by a second re-
viewer, for quality assurance.
Coding, aggregation and classification of outcomes
Outcome domains will be listed in a spreadsheet and
coded with reference to the taxonomy proposed by the
COMET Initiative (forthcoming). The Wilson and
Cleary conceptual model of patient outcomes will be
used initially to sort outcomes between biological and
physiological factors, symptoms, functioning, general
health perceptions and overall quality of life [32].
Members of the advisory panels will meet to review
and discuss the initial list of outcomes and may make
suggestions for additional outcomes, aggregating out-
comes or changing terminology and definitions of each
outcome to make them accessible in terms of language.
Phase 2: rating the importance of outcome domains
We will carry out a Delphi survey following recom-
mended practices in the development of core out-
come sets.
Stakeholders
We will engage relevant UK charities to advertise the
opportunity to families of children with rolandic epilepsy
to participate in the survey (e.g. Young Epilepsy,
Epilepsy Action, Epilepsy Research, Epilepsy Society,
Roald Dahl’s Marvellous Children’s Charity, epilepsy
charities in Scotland, Wales and Northern Ireland, Cere-
bra and the umbrella groups Joint Epilepsy Council and
Neurological Alliance). Health, education and neuro-
psychology professionals (e.g. paediatricians, paediatric
neurologists, epilepsy nurses, clinical and educational
psychologists) will be invited to participate through pro-
fessional societies and special interest groups (e.g. British
Paediatric Neurology Association, Royal College of
Nursing, Epilepsy Nurses Association, Royal College of
Paediatrics and Child Health, British Academy of
Childhood Disability and British Association for
Community Child Health, neurological and neuro-
psychology special interest groups of the British
Psychological Society, Medicines for Children
Research Network, NHS regional Paediatric Epilepsy
Networks and Cochrane Epilepsy). We will seek to
engage with general practitioners, health services
managers, commissioners and policymakers through
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the Paediatric Neurosciences Clinical Reference
Group. We will also use social network sites to link
with health professionals through online communities
(e.g. WeCYPnurses and #ExpofCare).
Survey administration
Potential participants will be invited to register through
an online system or by contacting the study team and
document their consent to take part. For families we will
record the age of the child, the region of the UK where
they live and ethnicity. We will ask whether the child
wants to take part in the survey themselves independ-
ently from their parents. Whilst we suspect this task
may be cognitively difficult for some children, particu-
larly younger children, we want to be as inclusive as
possible and will consider ways to modify the task for
children in consultation with our young people’s advis-
ory panel. For professionals we will record speciality
(paediatrician, neurologist, nurse etc.) and the region of
the UK in which they work. There is no formal sample-
size calculation appropriate for this type of study; neither
are there are recommendations for the number of partic-
ipants to include in a Delphi survey. We will continue to
recruit until we are satisfied that we have diversity of
participants from all stakeholder groups. Although we
target around 50–100 participants from each stakeholder
group, we propose 20–30 to be the minimum. The
number of each type of professional is also a function of
what is realistically possible; for instance, there are fewer
than 100 paediatric neurologists in total in the UK.
Registration will imply consent to participate in the
surveys. Each participant will have a unique identifier so
we are able monitor their responses, identify their stake-
holder group, and send reminder messages to non-
responders. The survey will be administered using the
COMET Initiative DelphiManager software.
Delphi survey
The first round of the survey will show the list of out-
comes identified in the review and endorsed by the ad-
visory panels. Participants will be asked to rate the
importance of measuring each outcome domain in
research using a 9-point scale, where response options
1–3 will indicate “less important”, options scored 4–6 as
“important but not critical”, and 7–9 as “crucially im-
portant”. An optional free-text box will enable partici-
pants to explain responses or raise issues. There will also
be an option to respond “not sure”/“don’t know”. In the
first round participants will be offered the opportunity
to identify any additional aspects of health they feel are
important but have not been included. These will be
considered for inclusion prior to round 2 based on
whether or not they are already conceptually represented
by an existing outcome domain.
The ratings of importance will be aggregated separ-
ately for families and professionals. Provided there are
sufficient numbers of responses, we may explore differ-
ences between children and parents and between sub-
categories of health professionals. We expect instances
where one stakeholder group but not the other indicates
domains more or less important.
Rounds 2 and 3 of the Delphi survey will present par-
ticipants with the results from the previous round. All
participants will see aggregated results for each separate
stakeholder group and their own personal ratings from
the previous round. Providing feedback from all stake-
holder groups separately is proposed to enhance consen-
sus between the groups [33]. They will be asked to
reflect on the feedback and rate again the importance of
each outcome in research with free-text boxes to indi-
cate the rationale for their decisions and any changes.
In judging consensus, we will examine survey re-
sponses by families and health professionals separately.
Over three rounds we expect to identify categories of (1)
most important “core” outcomes agreed by most stake-
holders (>70% in each stakeholder group rated 7–9), (2)
less important outcomes agreed by most stakeholders (>
70% in each stakeholder group rated 1–3), and (3) those
where there is partial or no agreement across stake-
holder groups.
Final meeting
A face-to-face meeting will be convened to ratify a final
core set of outcomes. The final round of the Delphi sur-
vey participants will be invited to volunteer to take part
in this meeting. We will select at random from those
who volunteer to seek a mix of young people, parents
and professionals; around 20 participants in total will be
ideal. Facilitated small group and plenary discussions
and potentially card-sorting techniques (such as modi-
fied Q-sorting) [34] will be used to seek consensus on
those outcome domains where there is disagreement.
Phase 3: how to measure the key outcomes
Having decided which core outcome domains to meas-
ure, the next stage is to identify ways to assess the out-
comes with reference to published guidance [35]. We
will search for candidate outcome measures and appraise
peer-reviewed evidence of measurement properties of
those measures with reference to criteria for acceptable
measurement properties [36]. The guideline for selecting
outcome measures recommends a comprehensive sys-
tematic review be conducted for each outcome domain
[35]. Given one of the purposes of this study is to inform
outcomes to be measured in a subsequent trial starting
in 2019, systematic reviews of all outcome domains is
not feasible. Therefore, in this study, we will carry out a
proportionate review of measures for each outcome with
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reference to methods for assessing outcome recorded in
our initial review of trials, and focus particularly on
reviewing patient-reported outcome measures.
For patient-reported outcome measures, including
preference-based measures, we will review which ques-
tionnaires include content that matches more closely the
outcome domains selected for the COS. Candidate
measurement tools will be discussed with our advisory
panels to identify measures judged to be most acceptable
to children and parents.
Search strategy
We will conduct a search for evaluations of the meas-
urement properties of each candidate patient-reported
outcome measure assessing epilepsy-specific quality of
life. A previous review has identified the main likely con-
tenders [8]. Electronic searches will be run using the
names and acronyms of the measures combined with
terms for children, and terms for measurement proper-
ties (e.g. validity, reliability, responsiveness). Search
strategies and dates of searches will be recorded. Search
results will be managed in reference management software.
Types of studies
Eligible publications will be evaluations of measurement
properties. We will only include evaluations of English-
language versions of the questionnaires [37]. Only
English-language papers are included.
Types of participants
The participants are children with epilepsy ages 5–16 years.
Exclusion criteria
Studies that include children with epilepsy but where
the focus is more on any associated impairments (e.g.
cerebral palsy, autism) will be excluded.
Deciding eligibility
The study researcher will screen titles and abstracts and
select references. If there are any doubts about eligibility
the final decision will be made in consultation with
other members of the research team. A PRISMA flow
chart will be used to record each stage of the study se-
lection process [26].
Data extraction
The study researcher will extract evidence of measure-
ment properties from included studies and record a
structured appraisal of the methodological quality of the
study [38].
Synthesis
Evidence of measurement properties for each patient-
reported outcome measure will be considered individually
and a summary appraisal rating given based on methodo-
logical quality, consistency of exceeding recommended
criteria and replication of performance, especially by
groups other than the developers.
Finally, our advisory panels will also be consulted
about (1) preferences for where assessments should take
place ideally, (2) how frequently and how long each
assessment should last, (3) ways to make assessment
more engaging and (4) preferences for duration of follow
up in the trial.
Dissemination
The full report and academic publication will report
with reference to the Core Outcome Set–Standards for
Reporting (COS-STAR) statement and checklist [39].
We will also produce a plain-language summary for
non-academic audiences and an easy-read version for
children. We will also seek to tell people the results and
implications via social media using video and audio files.
Discussion
The proposed methods will produce a COS for evalu-
ative research of interventions aiming to improve the
health of children with rolandic epilepsy. The findings
will also inform decisions about outcomes to be
measured in audits such as Epilepsy12 [28] and also
routinely collected service outcomes. The findings may
also be generalised to other types of common child-
hood epilepsy. We debated whether the scope of this
work should be broader to include other epilepsy syn-
dromes. The aim of our decision to focus principally
on rolandic epilepsy as an exemplar is to avoid pref-
erences for outcomes that might be affected by in-
cluding children who have associated conditions such
as autism or cerebral palsy.
The scope of our work is primarily in the UK but may
have broader international relevance. Studies such as
this, which are dependent on engaging families and
health professionals, are always influenced by the views
of the self-selecting sample of people who choose to
participate. Thus the COS we propose will benefit from
wider consultation once published, and potentially repli-
cation to refine either which health domains to measure
or how to measure them. Of course new ways to
measure the outcomes may also appear in time. There-
fore, whilst the findings will inform a subsequent rando-
mised controlled trial as part of this programme of
research, and help improve the consistency of epilepsy
research in the short term, it will benefit from being
reviewed in future.
A number of decisions have to be made when design-
ing a study to develop a COS [13]. Although we are not
undertaking new qualitative research in this study, there
can be a place for qualitative research in the early stages
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to seek and capture first hand which aspect of health the
patients and carers value and how they articulate these
potential outcomes [40]. We are reviewing published
qualitative research on children’s and parents’ prefer-
ences that may elicit preferences for important outcome
domains; however, we are not undertaking new qualita-
tive research in this study. We invested substantially in
advisory panels to enable children and young people
with epilepsy and parents to be involved as partners in
the process and ensure we use accessible language. The
reviews of previous research have also been determined
pragmatically rather than designed to be exhaustive.
Selection of measures for each domain in the core
outcome set will be based on a limited review, compre-
hensive systematic reviews for each domain could be
planned in future research. Despite the limitations we
consider the methodology proportionate to produce the
core outcome set expediently, and representing value for
the funding agency [41].
Selection of which stakeholders to include was another
decision we debated. In addition to patients, carers and
health professionals, some developers of core outcome
sets have engaged pharmaceutical and/or other industry
partners. We decided not to engage commercial part-
ners; whilst drug treatment is a mainstay for seizure
control it is not the only intervention within our scope.
Also, the ethos of our programme of research is to
encourage a broader patient-relevant and family-focused
outcome framework to guide health services [27]. Our
definition of health professionals includes managers and
commissioners as well as clinical staff. We will report
the extent to which we were able to engage professionals
with less specific interest in epilepsy and any methods
that were successful. Some core outcome set developers
advocate the engagement of clinical trialists as a separate
stakeholder group. However our team, which includes
clinical trialists, decided this was not a vital group
compared to families and clinicians.
Details of the core outcome set we recommend will be
disseminated in a variety of ways and thereby the core
outcome set will be made available for researchers to
consider for implementation in evaluative research and
other applications.
Trial status
This study is not a trial. We have not begun recruitment
for the Delphi study at the time of submission; recruit-
ment will begin in January 2018 subject to ethics
approvals being confirmed.
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